Phase 3 trial data show that zalunfiban administered on first medical contact significantly improved preprocedural coronary flow and 30-day clinical outcomes in STEMI.

Supported by phase 3 FENhance 1, FENhance 2, and FENtrepid trial results, oral fenebrutinib reduced relapse rates and showed numerical benefits in delaying disability progression across the MS ...

A powerful new lab-made opioid is moving through the illegal US drug supply, and federal officials warn it could keep spreading. The drug, called cychlorphine, may be up to 10 times stronger than ...

Findings show reductions in inappropriate medication, medication underuse and overuse, and missing vaccinations ...

Highest ASCVD risk at follow-up seen for those who remained in or transitioned into low exposure categories over one year ...